NEW YORK (GenomeWeb) – Genomic Health officials said this week that changes are in the works for the report the company returns to physicians as part of its Oncotype DX prostate cancer risk test.
NEW YORK (GenomeWeb) – Genomic Health officials said this week that changes are in the works for the report the company returns to physicians as part of its Oncotype DX prostate cancer risk test.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.